CN101679955A - 生产软骨素的细菌及生产软骨素的方法 - Google Patents
生产软骨素的细菌及生产软骨素的方法 Download PDFInfo
- Publication number
- CN101679955A CN101679955A CN200880013071A CN200880013071A CN101679955A CN 101679955 A CN101679955 A CN 101679955A CN 200880013071 A CN200880013071 A CN 200880013071A CN 200880013071 A CN200880013071 A CN 200880013071A CN 101679955 A CN101679955 A CN 101679955A
- Authority
- CN
- China
- Prior art keywords
- leu
- ile
- lys
- glu
- asn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000894006 Bacteria Species 0.000 title claims abstract description 143
- 229920002567 Chondroitin Polymers 0.000 title claims abstract description 9
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 title claims abstract description 9
- 238000000034 method Methods 0.000 title claims description 40
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 72
- 101150089127 kfoC gene Proteins 0.000 claims abstract description 28
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 claims abstract description 16
- HDYANYHVCAPMJV-UHFFFAOYSA-N Uridine diphospho-D-glucuronic acid Natural products O1C(N2C(NC(=O)C=C2)=O)C(O)C(O)C1COP(O)(=O)OP(O)(=O)OC1OC(C(O)=O)C(O)C(O)C1O HDYANYHVCAPMJV-UHFFFAOYSA-N 0.000 claims abstract description 16
- HDYANYHVCAPMJV-USQUEEHTSA-N udp-glucuronic acid Chemical compound O([P@](O)(=O)O[P@](O)(=O)OC[C@H]1[C@@H]([C@H]([C@@H](O1)N1C(NC(=O)C=C1)=O)O)O)[C@H]1O[C@@H](C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O HDYANYHVCAPMJV-USQUEEHTSA-N 0.000 claims abstract description 16
- 230000000968 intestinal effect Effects 0.000 claims description 82
- 108020004414 DNA Proteins 0.000 claims description 54
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 26
- 230000001580 bacterial effect Effects 0.000 claims description 22
- 235000018102 proteins Nutrition 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 108010009115 chondroitin synthase Proteins 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 18
- 239000002773 nucleotide Substances 0.000 claims description 16
- 125000003729 nucleotide group Chemical group 0.000 claims description 16
- 235000001014 amino acid Nutrition 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 230000008034 disappearance Effects 0.000 claims description 14
- 238000003780 insertion Methods 0.000 claims description 14
- 230000037431 insertion Effects 0.000 claims description 14
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 11
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 10
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 10
- 108020004635 Complementary DNA Proteins 0.000 claims description 8
- 238000009396 hybridization Methods 0.000 claims description 7
- 101100167242 Escherichia coli kfoC gene Proteins 0.000 claims description 5
- 238000006345 epimerization reaction Methods 0.000 claims description 5
- 102100021436 UDP-glucose 4-epimerase Human genes 0.000 claims description 3
- 108010075202 UDP-glucose 4-epimerase Proteins 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 abstract description 3
- 238000012258 culturing Methods 0.000 abstract description 2
- 241000282326 Felis catus Species 0.000 description 27
- 102220369445 c.668T>C Human genes 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 20
- 102220023257 rs387907546 Human genes 0.000 description 20
- 150000004676 glycans Chemical class 0.000 description 18
- 229920001282 polysaccharide Polymers 0.000 description 14
- 239000005017 polysaccharide Substances 0.000 description 14
- 102220023256 rs387907547 Human genes 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 13
- 102220369447 c.1352G>A Human genes 0.000 description 12
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 150000002016 disaccharides Chemical class 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 229940097043 glucuronic acid Drugs 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 7
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 7
- KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 description 7
- 102220369446 c.1274G>A Human genes 0.000 description 6
- 239000002054 inoculum Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 102220004457 rs11567847 Human genes 0.000 description 6
- 102220023258 rs387907548 Human genes 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000009182 swimming Effects 0.000 description 6
- 241000588722 Escherichia Species 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 230000008521 reorganization Effects 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 101150111062 C gene Proteins 0.000 description 4
- 108010038807 Oligopeptides Proteins 0.000 description 4
- 102000015636 Oligopeptides Human genes 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000013611 chromosomal DNA Substances 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 4
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 241000589220 Acetobacter Species 0.000 description 3
- 244000235858 Acetobacter xylinum Species 0.000 description 3
- 235000002837 Acetobacter xylinum Nutrition 0.000 description 3
- 108010067770 Endopeptidase K Proteins 0.000 description 3
- 241000588698 Erwinia Species 0.000 description 3
- 241000588748 Klebsiella Species 0.000 description 3
- 108010064696 N,O-diacetylmuramidase Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241000606856 Pasteurella multocida Species 0.000 description 3
- 241000589180 Rhizobium Species 0.000 description 3
- 102000004896 Sulfotransferases Human genes 0.000 description 3
- 108090001033 Sulfotransferases Proteins 0.000 description 3
- 241000605118 Thiobacillus Species 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229940051027 pasteurella multocida Drugs 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000019635 sulfation Effects 0.000 description 3
- 238000005670 sulfation reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 101710153593 Albumin A Proteins 0.000 description 2
- 102000037716 Chondroitin-sulfate-ABC endolyases Human genes 0.000 description 2
- 108090000819 Chondroitin-sulfate-ABC endolyases Proteins 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 241000588915 Klebsiella aerogenes Species 0.000 description 2
- 241000316848 Rhodococcus <scale insect> Species 0.000 description 2
- 241000187693 Rhodococcus rhodochrous Species 0.000 description 2
- 241000589196 Sinorhizobium meliloti Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000012262 fermentative production Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 229950006191 gluconic acid Drugs 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- -1 methane amide Chemical class 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- CBPKXFJDLCLUHE-KEWYIRBNSA-N (3R,4R,5R,6R)-3-(ethylamino)-6-(hydroxymethyl)oxane-2,4,5-triol Chemical compound C(C)N[C@H]1C(O)O[C@@H]([C@@H]([C@@H]1O)O)CO CBPKXFJDLCLUHE-KEWYIRBNSA-N 0.000 description 1
- 244000283763 Acetobacter aceti Species 0.000 description 1
- 235000007847 Acetobacter aceti Nutrition 0.000 description 1
- 241000605222 Acidithiobacillus ferrooxidans Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 101710117545 C protein Proteins 0.000 description 1
- 102000011413 Chondroitinases and Chondroitin Lyases Human genes 0.000 description 1
- 108010023736 Chondroitinases and Chondroitin Lyases Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000588694 Erwinia amylovora Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000589216 Komagataeibacter hansenii Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241001135312 Sinorhizobium Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- PNVLWFYAPWAQMU-CIUDSAMLSA-N Val-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)C(C)C PNVLWFYAPWAQMU-CIUDSAMLSA-N 0.000 description 1
- 241000204366 Xylella Species 0.000 description 1
- 241000204362 Xylella fastidiosa Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229950006790 adenosine phosphate Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940107200 chondroitin sulfates Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940092559 enterobacter aerogenes Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
通过如下方法生产软骨素:培养引入了衍生自大肠杆菌K4株的kfoA基因和衍生自大肠杆菌K4株的kfoC基因并具有产生软骨素之能力的产生UDP-葡糖醛酸的细菌;以及从该细菌中收集软骨素。
Description
[0001]
技术领域
本发明涉及生产软骨素的细菌及生产软骨素的方法。
[0002]
背景技术
软骨素是一种包括葡糖醛酸(GlcUA)残基和N-乙基-D-半乳糖胺(GalNAc)残基的二糖重复结构的多糖(-GlcUAβ(1-3)-GalNAcβ(1-4)-,在本说明书中,也称为软骨素糖骨架)。硫酸软骨素是由软骨素的硫酸化组成的多糖。
传统上从动物的软骨、器官等提取和纯化软骨素和硫酸软骨素。然而,近年来,因为诸如软骨和器官之类的材料不足,已经研究了人工合成对于软骨素和硫酸软骨素而言常见的糖骨架的技术。
[0003]
已经报道了软骨素合酶,其通过交替地将GlcUA和GalNAc从它们的供体底物转移至受体寡糖而产生软骨素,并且已经提出了应用该酶生产软骨素的方法。
J.Biol.Chem.275(31),24124-24129(2000)公开了衍生自多杀性巴氏杆菌(Pasteurella multocida)的软骨素合酶。
此外,WO 2003/102193和WO 2003/102194公开了衍生自人类的软骨素合酶。
此外,US 2003-0109693(JP 2003-199583A)公开了由大肠杆菌(Escherichia coli)K4株产生的新软骨素合酶(KfoC)。
然而,在通过酶方法生产软骨素的情况下,需要制备昂贵的材料,诸如作为受体的寡糖和作为GlcUA和GalNAc的供体的糖核苷酸,因此期望应用更便宜的材料生产软骨素的方法。
[0004]
已知大肠杆菌K4株产生具有软骨素骨架结构的多糖作为荚膜。然而,其结构由包括GalNAc残基、GlcUA残基和果糖残基的三糖的重复单元组成,其中所述的果糖残基与GlcUA残基的C3-羟基连接。此外,在大肠杆菌中已经检测到了超过100种化学上不同的荚膜多糖。例如,大肠杆菌K5株产生具有肝素/硫酸乙酰肝素的糖骨架的荚膜多糖K5(J.Biol.Chem.,272(5),p2682-2687,1997)。然而,还不知道有产生软骨素本身的大肠杆菌的存在。因此,应用大肠杆菌生产软骨素的方法是未知的。
尽管美国公开专利申请2007-0281342公开了通过应用引入了衍生自多杀性巴氏杆菌的软骨素合酶基因的重组革兰氏阳性菌生产软骨素的方法,然而期望在软骨素的发酵生产中有更进一步的发展。
[0005]
发明的公开内容
本发明的一个目的是提供能够生产软骨素的新微生物,以及应用该微生物生产软骨素的新方法。
[0006]
本发明的发明人进行了深入的研究,结果发现引入了衍生自大肠杆菌K4株kfoA和kfoC基因的产生UDP-葡糖醛酸的细菌诸如大肠杆菌K5株高效地产生软骨素,因此完成了本发明。
[0007]
本发明的一个目的是提供引入了衍生自大肠杆菌K4株的kfoA基因和衍生自大肠杆菌K4株的kfoC基因并且具有产生软骨素的能力的产生UDP-葡糖醛酸的细菌。
在本文中,所述的衍生自大肠杆菌K4株的kfoA基因优选为编码选自由以下(A)和(B)所组成的组的蛋白的基因:
(A)包含SEQ ID NO:2的氨基酸序列的蛋白质;以及
(B)包含SEQ ID NO:2的氨基酸序列的蛋白质,其包括一个或几个氨基酸的替换、缺失、插入或添加并具有UDP-葡萄糖-4-差向异构酶活性。
所述的衍生自大肠杆菌K4株的kfoA基因优选为选自由以下(a)和(b)组成的组的DNA:
(a)包含SEQ ID NO:1的核苷酸序列的DNA;和
(b)在严格条件下与包含和SEQ ID NO:1互补的核苷酸序列的DNA杂交并编码包含UDP-葡萄糖-4-差向异构酶活性的蛋白的DNA。
此外,所述的衍生自大肠杆菌K4株的kfoC基因优选为编码选自由以下(C)和(D)所组成的组的蛋白的基因:
(C)包含SEQ ID NO:4的氨基酸序列的蛋白质;以及
(D)包含SEQ ID NO:4氨基酸序列的蛋白质,其包括一个或几个氨基酸的替换、缺失、插入或添加并具有软骨素合酶活性。
此外,所述的衍生自大肠杆菌K4株的kfoC基因优选为选自由以下(c)和(d)组成的组的DNA:
(c)包含SEQ ID NO:3的核苷酸序列的DNA;和
(d)在严格条件下与包含和SEQ ID NO:3互补的核苷酸序列的DNA杂交并编码具有软骨素合酶活性的蛋白的DNA。
此外,所述的衍生自大肠杆菌K4株的kfoC基因优选为编码选自由以下(E)和(F)所组成的组的蛋白的基因:
(E)包含SEQ ID NO:6氨基酸序列的蛋白质;以及
(F)包含SEQ ID NO:6氨基酸序列的蛋白质,其包括一个或几个氨基酸的替换、缺失、插入或添加并具有软骨素合酶活性。
此外,所述的衍生自大肠杆菌K4株的kfoC基因优选为选自由以下(e)和(f)组成的组的DNA:
(e)包含SEQ ID NO:5的核苷酸序列的DNA;和
(f)在严格条件下与包含和SEQ ID NO:5互补的核苷酸序列的DNA杂交并编码具有软骨素合酶活性的蛋白的DNA。
所述的产生UDP-葡糖醛酸的细菌优选为大肠杆菌K5株。
[0008]
本发明的另一目的是提供生产软骨素的方法,其至少包括以下步骤(1)和(2):
(1)培养如上所述的细菌;以及
(2)从该培养物中收集软骨素。
[0009]
本发明的另一目的是提供生产硫酸软骨素的方法,其包括:通过如上所述的方法生产软骨素;以及然后将该软骨素硫酸化以产生硫酸软骨素。
[0010]
本发明的另一目的是提供包含衍生自大肠杆菌K4株的kfoA基因和衍生自大肠杆菌K4株的kfoC基因的载体。
[0011]
附图简述
图1是显示了用于表达kfoA和kfoC基因的载体结构的图。
图2是显示了kfoA和kfoC蛋白表达的图(照片)。泳道1显示没有引入质粒的菌株(对照),泳道2显示引入了pTrcHis-kfoCA的菌株,以及M显示分子量标记。
图3显示了对于用软骨素酶ABC(cABC)处理的级分L(A)、没有用cABC处理的级分L(B)以及用热灭活的cABC处理的级分L(C),采用荧光HPLC系统的二糖组成分析的结果。
图4显示了对于用cABC处理的级分E(A)、没有用cABC处理的级分E(B)以及用热灭活的cABC处理的级分E(C)的荧光二糖分析的结果。
图5显示了对于用cABC处理的级分S(A)、没有用cABC处理的级分S(B)以及用热灭活的cABC处理的级分S(C)的荧光二糖分析的结果。
图6显示了对于用cABC处理的软骨素标准品(A)、用cABC处理的软骨素标准品和用cABC处理的级分L的混合物(B)的荧光二糖分析的结果。
图7是显示了应用(A)抗-KfoC抗体(EK-C)作为一抗、(B)抗-KfoA抗体(EK-A)作为一抗以及(C)正常兔血清,KfoA、KfoC和KfoΔC蛋白表达的图(照片)。泳道1和5显示分子标记MagicMarkXP标准品(Invitrogen),泳道2显示引入了pTrcHis-kfoCA的菌株,泳道3显示引入了pTrcHis-kfoΔCA的菌株,以及泳道4显示引入了pTrcHis-kfoA的菌株。
[0012]
优选实施方案的描述
在下文中,将详细地描述本发明。
<1>本发明的细菌
本发明的细菌是引入了衍生自大肠杆菌K4株的kfoA和kfoC基因的产生UDP-葡糖醛酸且具有产生软骨素的能力的细菌。
“产生UDP-葡糖醛酸的细菌”提供了UDP-葡糖醛酸,其可被用于产生包含葡糖醛酸的多糖。对“产生UDP-葡糖醛酸的细菌”没有限制,只要其产生UDP-葡糖醛酸,并且其实例包括属于葡糖酸醋杆菌属的细菌,诸如汉森葡糖酸醋杆菌(Gluconacetobacter hansenii)和木葡糖酸醋杆菌(Gluconacetobacter xylinus);属于根瘤菌(Rhizobium)属的细菌,诸如Rhizobium meffloti;属于醋酸杆菌(Acetobacter)属的细菌,诸如木醋杆菌(Acetobacter xylinum);属于欧文氏菌(Erwinia)属的细菌,诸如解淀粉欧文氏菌(Erwinia amylovora);属于硫杆菌(Thiobacillus)属的细菌,诸如氧化亚铁硫杆菌(Thiobacillus ferrooxidans);属于木杆菌属(Xylella)属的细菌,诸如苛养木杆菌(Xylella fastidiosa);属于中华根瘤菌属(Sinorhizobium)属的细菌,诸如苜蓿中华根瘤菌(Sinorhizobiummeliloti);属于红球菌(Rhodococcus)属的细菌,诸如玫瑰色红球菌(Rhodococcus rhodochrous);属于克雷伯氏菌(Klebsiella)属的细菌,诸如产气克雷伯氏菌(Klebsiella aerogenes);属于肠杆菌(Enterobacter)属的细菌,诸如产气肠杆菌(Enterobacter aerogenes);属于埃希氏杆菌(Escherichia)属的细菌,诸如大肠杆菌。
“产生UDP-葡糖醛酸的细菌”优选为属于埃希氏杆菌属并能产生UDP-葡糖醛酸的细菌,以及更优选为属于大肠杆菌并能产生UDP-葡糖醛酸的细菌。
其具体的实例包括大肠杆菌K5菌株。K5菌株被保藏在美国典型培养物保藏所(American Type Culture Collection)(ATCC:P.O.Box 1549,Manassas,VA 20108,美利坚合众国),登录号为ATCC23506并且可从ATCC的目录或主页上获得。
待引入kfoA和kfoC基因的菌株可以是大肠杆菌K5菌株的衍生菌株,并且此类衍生菌株可通过遗传重组将基因突变引入该大肠杆菌K5株或将基因引入该大肠杆菌K5株而获得。也就是说,本发明的细菌的一方面包括:通过将衍生自大肠杆菌K4株的kfoA和kfoC基因引入大肠杆菌K5株而获得的菌株;通过将衍生自大肠杆菌K4株的kfoA和kfoC基因引入大肠杆菌K5株并进一步引入基因突变而获得的菌株;以及通过将衍生自大肠杆菌K4株的kfoA和kfoC基因引入大肠杆菌K5株并进一步引入另一基因而获得的菌株。
[0013]
衍生自大肠杆菌K4株的kfoA基因的实例包括编码包含SEQ ID NO:2氨基酸序列的蛋白质的DNA,以及包含SEQ ID NO:1的核苷酸序列的DNA。
一般而言,在一个或几个组成蛋白质的氨基酸中的替换、缺失、插入或添加对该蛋白质的活性没有影响,因此,许多情况下,衍生自大肠杆菌K4株的kfoA基因可以是编码这样的蛋白的基因,所述蛋白包含SEQ ID NO:2氨基酸序列,并且包括一个或几个氨基酸的替换、缺失、插入或添加并具有UDP-葡萄糖-4-差向异构酶活性。
本文所使用的短语“一个或几个氨基酸”是指可能引起替换、缺失、插入或添加,但不会损害UDP-葡萄糖-4-差向异构酶活性的氨基酸数目。具体而言,该数目例如是1至20的整数,优选为1至10的整数,更优选为1至5的整数。
同时,衍生自大肠杆菌K4株的kfoA基因可以是编码这样的蛋白的基因,所述蛋白包含与SEQ ID NO:2的整个序列的同一性不少于90%、优选同一性不少于95%、更优选同一性不少于98%的氨基酸序列,并具有UDP-葡萄糖-4-差向异构酶活性。
[0014]
可通过PCR应用大肠杆菌K4株的染色体DNA作为模版获得衍生自大肠杆菌K4株的kfoA基因。
大肠杆菌K4株已被保藏在美国典型培养物保藏所(American TypeCulture Collection)(ATCC),登录号为ATCC23502并且可从ATCC的目录或主页上获得。
可通过点特异性诱变(Kramer,W.和Frits,H.J.,Meth.Enzymol.,154,350(1987);Kunkel,T.A.等,Meth.Enzymol.,154,367(1987))等修饰SEQID NO:1的核苷酸序列以将一个或几个氨基酸的替换、缺失、插入或添加引入到SEQ ID NO:2的氨基酸序列上,从而获得编码包括一个或几个氨基酸的替换、缺失、插入或添加的包含SEQ ID NO:2的氨基酸序列,或与SEQ ID NO:2的整个序列的同一性不少于90%的氨基酸序列,且具有UDP-葡萄糖-4-差向异构酶活性的蛋白质的基因。
还可通过以下方法获得该基因:通过在严格条件下与包含和SEQ IDNO:1的核苷酸序列或其部分序列互补的核苷酸序列的DNA杂交来筛选编码具有UDP-葡萄糖-4-差向异构酶活性的蛋白质的DNA。
术语“严格条件”是指在其中形成所谓的特异性杂交、且不形成非特异性杂交的条件(参见Sambrook,J.等,分子克隆:实验室手册,第二版,Cold Spring Harbor Laboratory Press(1989),等)。“严格条件”的具体实例包括这样的条件:在42℃在含有50%甲酰胺、4×SSC、50mMHEPES(pH 7.0)、10×Denhardt溶液、100μg/ml鲑精DNA的溶液中杂交,在室温下用2×SSC、0.1%SDS溶液洗涤,并且然后在60℃用0.1×SSC、0.1%SDS洗涤。
可通过将得到的基因引入到合适的宿主中以表达该蛋白并然后根据J.Biol.Chem.,277(24),p21567-21575,2002中描述的方法测量UDP-葡萄糖-4-差向异构酶活性,从而判断如上所述获得的基因是否编码具有UDP-葡萄糖-4-差向异构酶活性的蛋白。
[0015]
衍生自大肠杆菌K4株的kfoC基因的实例包括编码包含SEQ ID NO:4的氨基酸序列的蛋白质的DNA以及包含SEQ ID NO:3的核苷酸序列的DNA。衍生自大肠杆菌K4株的kfoC基因的实例还包括编码包含SEQID NO:6氨基酸序列的蛋白质的DNA以及包含SEQ ID NO:5的核苷酸序列的DNA。
衍生自大肠杆菌K4株的kfoC基因可以是编码这样的蛋白的基因,所述蛋白包含SEQ ID NO:4或6的氨基酸序列,并且包括一个或几个氨基酸的替换、缺失、插入或添加并且具有软骨素合酶活性。
衍生自大肠杆菌K4株的kfoA基因可以是编码这样的蛋白的基因,所述蛋白包含与SEQ ID NO:4或6的整个序列的同一性不少于90%、优选同一性不少于95%、更优选同一性不少于98%的氨基酸序列,并具有软骨素合酶活性。
本文所使用的术语“软骨素合酶活性”是指将GlcUA从GlcUA供体或将GalNAc从GalNAc供体交替地转移至糖链的非还原端的活性。
[0016]
可通过PCR应用大肠杆菌K4株的染色体DNA作为模版来获得衍生自大肠杆菌K4株的kfoC基因。此外,还可根据WO2007/145197中描述的方法获得编码SEQ ID NO:6的氨基酸序列的kfoC基因,诸如包含SEQ ID NO:5的核苷酸序列的DNA。
可通过点特异性诱变等修饰SEQ ID NO:3或5的核苷酸序列以将一个或几个氨基酸的替换、缺失、插入或添加引入到SEQ ID NO:4或6的氨基酸序列上,从而获得编码包括一个或几个氨基酸的替换、缺失、插入或添加的包含SEQ ID NO:4或6的氨基酸序列,或与SEQ ID NO:4或6的整个序列的同一性不少于90%的氨基酸序列,并且具有软骨素合酶活性的蛋白质的基因。
还可通过以下方法获得该基因:通过在严格条件下与包含和SEQ IDNO:3或5的核苷酸序列或其部分序列互补的核苷酸序列的DNA杂交来筛选编码具有软骨素合酶活性的蛋白质的DNA。
术语“一个或几个”和“严格条件”的定义与上面描述的相同。
可通过将得到的基因引入至合适的宿主以表达该蛋白并然后根据US 2003-0109693(JP 2003-199583A)中描述的方法测量软骨素合酶活性,从而判断如上所述获得的基因是否编码具有软骨素合酶活性的蛋白。
[0017]
可通过将衍生自大肠杆菌K4株的kfoA基因和衍生自大肠杆菌K4株的kfoC基因引入至如上所述的产生UDP-葡糖醛酸的细菌中而获得本发明的细菌。
在本发明中使用的术语“引入”包括应用载体诸如质粒或噬菌体将两个基因引入到产生UDP-葡糖醛酸的细菌中,以及通过同源重组等将两个基因引入到产生UDP-葡糖醛酸的细菌的染色体上。
对在本文中应用的载体诸如质粒或噬菌体没有特别地限制,只要它们可以用于将基因引入到大肠杆菌中,它们的实例包括pTrcHis(Invitrogen公司)、pET载体(Novagen)和pGEX载体(AmershamPharmacia)。
在引入衍生自大肠杆菌K4株的kfoA基因和衍生自大肠杆菌K4株的kfoC基因时,可以使用该基因的天然启动子,但优选应用在大肠杆菌中强有力的启动子,诸如lac启动子、trp启动子、trc启动子、PR启动子或lacUV启动子。
可以一个接一个地引入或使用单个载体同时引入衍生自大肠杆菌K4株的kfoA基因和kfoC基因。更优选应用携带kfoA和kfoC基因两者的载体,诸如质粒或噬菌体,因为可以容易地完成所述基因的引入和表达。
可以这样引入衍生自大肠杆菌K4株的kfoA和kfoC基因,以使得将它们表达为与其它肽的融合蛋白。
其它肽的实例包括聚组氨酸标签和GST(谷胱甘肽-S-转移酶)标签。以融合蛋白形式表达基因产物是优选的,因为这样可以很容易地进行基因产物的检测(表达的确认)。
可通过已知的转化方法进行基因的引入。所述方法的实例包括电穿孔方法、DEAE-葡聚糖方法和磷酸钙方法。
可通过以下方法确认基因的引入:检测基因的方法,例如RT-PCR或RNA印迹;特别地检测重组蛋白质表达的方法,诸如蛋白质印迹;以及如上所述的活性测量方法。
如果所导入的衍生自大肠杆菌K4株的kfoA基因和衍生自大肠杆菌K4株的kfoC基因在产生UDP-葡糖醛酸的细菌中工作的话,则该细菌获得了产生软骨素作为荚膜多糖的能力。
[0018]
<2>生产软骨素的方法
本发明的生产软骨素的方法至少包括以下步骤(1)和(2)。
(1)培养本发明的细菌。
(2)从该培养物收集软骨素。
[0019]
可通过用于培养属于埃希氏杆菌属的细菌的一般方法进行所述培养。
对培养基没有特别的限制,只要其能用于培养属于埃希氏杆菌属的细菌,并且其优选实例包括LB培养基(Luria-Bertani培养基)(每升含有10.0g的细菌用胰蛋白胨、5.0g的细菌用酵母提取物和5.0g的NaCl)和CYG培养基(2.0%酪蛋白氨基酸、0.5%酵母提取物和0.2%葡萄糖,高压灭菌前调节pH至7.0)。在应用含有抗生素抗性基因的载体来引入基因的情况下,所述培养基优选含有相应于该基因的抗生素。
对培养条件没有特别地限制,只要属于埃希氏杆菌属的细菌能够生长即可,为了能高效地生产软骨素,优选在20至40℃培养8至72小时。
为了高效地生产软骨素,可以在板或流体培养基中预培养细菌。
[0020]
对从培养物中收集软骨素的方法没有特别地限制,只要能收集软骨素即可,并且其实例包括以下中描述的方法。具体而言,将收集的重组细胞重悬在PBS(磷酸盐缓冲的盐水)等中;用溶菌酶、DNA酶I和蛋白酶K处理该细胞;并且移除蛋白质。例如可通过用软骨素酶处理该级分并进行二糖组成分析来检测软骨素。
[0021]
<3>生产硫酸软骨素的方法
可通过进一步把从本发明中公开的重组细菌中制备的软骨素硫酸化而制备硫酸软骨素。
可通过已知的硫酸化糖胺聚糖的方法来进行所述的硫酸化,对所述方法没有特别地限制,其实例包括在JP 61-47701A中描述的方法。
此外,可应用用于将硫酸基团转移至软骨素的酶(磺基转移酶)来进行所述硫酸化。在存在3’-磷酸腺苷5’-磷酰硫酸(PAPS)作为硫酸根供体的情况下,磺基转移酶能通过对由本发明公开的重组细菌产生的软骨素作出反应而产生硫酸软骨素。用于将硫酸基团转移至软骨素的已知的磺基转移酶的实例包括软骨素6-O-硫酸基团转移酶(J.Biol.Chem.,275(28),21075-21080(2000))和半乳糖胺基聚糖4-硫酸根基团转移酶(JP2000-4877A).
[0022]
实施例
下面,将参考实施例详细地描述本发明。
[0023]
实施例1:制备KfoC/KfoA共表达载体
<KfoA基因的扩增>
应用大肠杆菌K4菌株的染色体DNA作为模板,根据J.Biol.Chem.,277卷,24期,21567-21575中描述的方法进行PCR,然后将得到的PCR产物插入到pTrcHis(组氨酸融合蛋白表达载体,Invitrogen)中,由此产生pTrcHis-kfoA。
所使用的引物如下:
K4A-SP:5′-CGGGATCCCGATGAGTATTCTTAATCAAGC-3′(SEQID NO:7)和
K4A-AS:5′-GGAATTCCGGCCAGTCTACATGTTTATCAC-3′(SEQID NO:8)。
[0024]
<KfoC基因的扩增>
应用大肠杆菌K4菌株的染色体DNA作为模板,根据P 2003-199583A中描述的方法进行PCR,然后将得到的PCR产物插入到pTrcHis中,由此产生pTrcHis-kfoC。
所使用的引物如下:
K4C-SP:5′-CGGGATCCCGATGAGTATTCTTAATCAAGC-3′(SEQID NO:9)和
K4C-AS:5′-GGAATTCCGGCCAGTCTACATGTTTATCAC-3′(SEQID NO:10).
[0025]
<pTrcHis-kfoCA的制备>
按下列方式从上述pTrcHis-kfoA和pTrcHis-kfoC制备pTrcHis-kfoCA。
首先,通过PCR将NotI-SalI位点引入pTrcHis-kfoC的C端序列。应用以下所示的引物进行PCR,以从kfoC的C端侧扩增pTrcHis-kfoC的全长,然后使得到的PCR产物自身连接,由此产生质粒pTrcHis-kfoC-NotI-SalI。
所使用的引物如下:
NotSal-pTrcHisC-rev:
5’-GCGGCCGCAAAACAGCCAAGCTTCGAATTC-3’(SEQ ID NO:11)和
NotSal-pTrcHisC-for:
5’-ACGCGTCGACGGCGGATGAGAGAAGATTTTCA-3’(SEQ ID NO:12)
[0026]
然后分别在核糖体结合位点(RBS)的上游以及pTrcHis-kfoA的kfoA的C端区域设计引物(NotI-RBS-KfoA-N:5’-GCGGCCGCAAAATTAAAGAGGTATATATTAATGTATCGA-3’(SEQID NO:13)和S alI-KfoA-C:5’-GTCGACCTCTCATCCGCCAAAACA-3’(SEQ ID NO:14)),并用于使用pTrcHis-kfoA作为模版的PCR。然后,将得到的PCR产物插入到pCR4-TOPO(Invitrogen),由此产生pCR4-TOPO-kfoA。
用NotI-SalI从pCR4-TOPO-kfoA切除含有kfoA的插入片段,并引入到pTrcHis-kfoC-NotI-SalI的NotI-SalI位点上,并且将得到的质粒命名为pTrcHis-kfoCA(图1)。
[0027]
实施例2
重组的KfoC和KfoA的共表达
通过电穿孔(细胞100μL,200Ω,25μF,2.5kV,小池0.1cm)将表达载体pTrcHis-kfoCA引入到大肠杆菌K5株中,由此产生大肠杆菌K5/pTrcHis-kfoCA株。将克隆转移到补充有100ppm氨苄青霉素的LB培养基中,并且然后将种子培养物在37℃温育过夜。将1mL所述种子培养物转移至20mL补充有100ppm氨苄青霉素的CYG培养基中。将重组的细菌在37℃培养3小时(OD600=1.8,1.7-2.0),并且然后往该培养物中添加IPTG,终浓度为1.0mM。将得到的培养物在37℃再培养5小时,以诱导重组蛋白的表达。
通过离心从900μL培养物中收集细菌细胞。使得到的细胞悬浮于90μL Laemmli缓冲液(×1)中。在沸水浴中加热10分钟后,使10μL上清液在5/20%滴度凝胶中进行SDS-PAGE,并转移至PVDF膜上,随后进行蛋白质印迹分析以检测重组蛋白的表达。应用稀释1/2,000的抗-Penta-His-HRP(QIAGEN)检测重组的组氨酸融合蛋白。结果,确认了重组蛋白KfoA和KfoC的表达(图2)。
[0028]
实施例3
制备多糖及通过二糖分析检测多糖
<细菌细胞的制备>
在补充有100ppm氨苄青霉素的LB培养基中培养大肠杆菌K5/pTrcHis-kfoCA株作为种子培养物。然后将该种子培养物(750μL)转移至补充有100ppm氨苄青霉素的CYG培养基(15mL)中,然后在37℃培养3小时。往该培养物中加入IPTG(终浓度:1mM),并且再培养5小时。
<培养物上清液的制备>
将该种子培养物(1mL)转移到补充有100ppm氨苄青霉素的CYG培养基(20mL)中,并且然后在37℃培养3小时。往该培养物中加入IPTG(终浓度:0.1mM),并且再培养5小时。
通过离心收集培养上清液。
[0029]
<多糖级分的制备>
通过以下三种方法从重组的细胞和培养物上清液制备多糖。
制备1)将上述得到的细菌重悬于PBS中,并在37℃用溶菌酶和DNA酶I处理1小时,随后在37℃用蛋白酶K处理1小时。然后,加热使酶失活,并且通过用70%硫酸铵沉淀来除去蛋白质。将得到的上清液级分针对10mM Tris-HCl(pH 8.0)透析,产生样本L。
[0030]
制备2)根据生产商的说明书,顺序地使用用于纯化质粒的试剂:P1(含有溶菌酶)、P2和P3(QIAGEN)处理上述得到的细菌。通过离心收集后,将上清液进行乙醇沉淀。通过离心收集沉淀,并且将沉淀重悬于100μL无菌水中。在37℃用DNA酶I处理该悬浮液1小时以消化DNA,随后在37℃用蛋白酶K处理1小时。然后,加热使酶失活,并且通过用70%硫酸铵沉淀来除去蛋白质。将得到的上清液级分针对10mMTris-HCl(pH 8.0)透析,产生样本E。
制备3)蒸发培养物上清液(20mL)至干燥。将干燥的物质溶解于1ml蒸馏水中。将得到的溶液针对10mM Tris-HCl(pH 8.0)透析,产生样本S。
[0031]
<通过二糖分析检测软骨素>
在37℃用在含有50mM NaOAc的50mM Tris-HCl缓冲液(pH 8.0)中的cABC(软骨素酶ABC,由Seikagaku公司生产)处理样本L、E和S(每一个为100μL)过夜。
作为对照,制备了没有用cABC处理的样本L、E和S以及用热失活的cABC处理的样本L、E和S。进行超滤以除去大小等于或大于10,000的大分子,并且通过应用荧光HPLC系统(J Biol Chem.2000Jul21;275(29):2269-2275)的二糖成分分析来分析所述样本(图3、4和5)。在HPLC系统中应用Senshu Pak Decosil C22(4.6I.D.×150mm)作为分离柱,并将荧光检测器的激发和发射波长分别设置为346nm和410nm。
结果,仅在用cABC处理的样本的情况下检测到特定峰。每一样本的二糖组分特征与图6(A)所示的用cABC处理软骨素标准品获得的样本的特征接近一致。同时,在将用cABC处理的软骨素标准品和用cABC处理的样本L混合的情况下,仅检测到一个峰,因此确定样本L含有软骨素(图6(B))。在样本E和S的情况下,得到了相同的结果(数据未给出)。
[0032]
实施例4
制备KfoΔC/KfoA共表达载体
<KfoΔC基因的扩增>
根据WO2007/145197中描述的方法,克隆了编码N-端截短的KfoC、包含SEQ ID NO:5核苷酸序列的DNA(KfoΔC基因)。将该KfoΔC基因插入到pTrcHis中以获得pTrcHis-kfoΔC。
<pTrcHis-kfoΔCA的制备>
应用限制性酶SphI和SmaI切割实施例1中制备的质粒pTrcHis-kfoCA。
通过使用相同的限制性酶消化质粒pTrcHis-kfoΔC而得到DNA片段(2.9kDa)。按照常规方法将该DNA片段插入到切割后的质粒的SphI-SmaI位点中,然后将得到的质粒命名为pTrcHis-kfoΔCA。
[0033]
实施例5
抗-KfoA和抗-KfoC抗体的制备
<抗-KfoA抗体的制备>
合成包含SEQ ID No:15的肽序列的寡肽(CIVSR RDGDI AESWSSPEKA NK,纯度:>70%),并通过常规方法将4mg该寡肽与KLH(钥孔虫戚血兰素)缀合。通过与完全佐剂混合来制备抗原溶液后,以2周的间隔进行免疫5次。确认了抗体滴度后,收集全血。从每一只兔的血液中分别获得48mL(样本A)和60mL(样本B)的抗-KfoA血清。应用蛋白A柱纯化后,从样本A中获得32ml IgG级分EK-A(IgG浓度:5.30mg/mL)。
[0034]
<抗-KfoC抗体的制备>
合成了包含SEQ ID No:16肽序列的寡肽(CQEPP GKENE TDRAAGK,纯度:>70%),并通过常规方法将4mg该寡肽与KLH(钥孔虫戚血兰素)缀合。通过与完全佐剂混合来制备抗原溶液后,以2周的间隔进行免疫5次。确认了抗体滴度后,收集全血。从每一只兔的血液中分别获得65mL(样本A)和39mL(样本B)的抗-KfoA血清。应用蛋白A柱纯化后,从样本A中获得了39ml IgG级分EK-A(IgG浓度:4.41mg/mL)。
[0035]
实施例6
以与实施例2中相同的方法将pTrcHis-kfoΔCA引入到大肠杆菌K5株中,得到大肠杆菌K5/pTrcHis-kfoΔCA株,并且培养该重组株以评估重组蛋白的表达。
将在补充有100ppm氨苄青霉素的LB培养基中培养的种子培养物(0.5mL)转移至补充有100ppm氨苄青霉素的CYG培养基(10mL)中,并随后在37℃培养1.5小时。加入IPTG(终浓度为:1mM)后,再继续培养4小时。从900μL该培养物中收集细菌细胞,并悬浮于90μLLaemmli缓冲液(×1)中。在废水浴中加热10分钟后,将10μL该上清液在7.5%凝胶上进行SDS-PAGE,并转移至PVDF膜上,随后进行蛋白质印迹分析以检测重组蛋白的表达。应用稀释至1/1,000的抗-KfoA抗体(EK-A)和抗-KfoC抗体(EK-C)用作用于检测重组蛋白KfoA、KfoC和kfoΔC的一抗。用抗-兔免疫球蛋白HRP(DAKO,#P0448)作为二抗。此外,应用大肠杆菌K5/pTrcHis-kfoCA和大肠杆菌K5/pTrcHis-kfoA进行相同的检验,以比较重组蛋白的表达水平。结果,在大肠杆菌K5/pTrcHis-kfoCA和大肠杆菌K5/pTrcHis-kfoA之间的kfoA和kfoC(kfoΔC)的表达水平没有大的区别(图7)。
[0036]
实施例7
制备多糖及通过二糖分析检测多糖
<细菌细胞的制备>
以与实施例3中相同的方式,在121℃高压灭菌5分钟后,从大肠杆菌K5/pTrcHis-kfoΔCA株、大肠杆菌K5/pTrcHis-kfoCA和大肠杆菌K5/pTrcHis-kfoA株制备细菌细胞和上清液。
<多糖级分的制备>
针对流动的自来水透析所述上清液(1mL)过夜,并然后冷冻干燥透析的溶液。将冷冻干燥的材料溶解于100μL 50mM Tris-HCl(pH8.0),以用作多糖级分。
[0037]
<通过二糖分析来检测软骨素>
以与实施例3中相同的方法,通过二糖成分分析来分析所获得的级分。通过荧光HPLC分析软骨素标准溶液(200μg/mL和100μg/mL)以制得软骨素的校准曲线。在软骨素浓度和不饱和二糖的峰面积ΔDi-0S之间的关系如等式-1所示。
[软骨素;μg/mL上清液]=
(0.000591×[峰面积]+1.219)/[浓度比率]
(r2=0.9984) (等式-1)
[0038]
在从大肠杆菌K5/pTrcHis-kfoΔCA、大肠杆菌K5/pTrcHis-kfoCA制备的样本中检测与不饱和二糖一致的峰(ΔDi-0S)(数据未显出)。表1显示了应用等式-1计算的重组培养物中的软骨素浓度的结果。
[0039]
表1在重组菌株的培养物中软骨素含量的比较
[0040]
通过比较大肠杆菌K5/pTrcHis-kfoΔCA和大肠杆菌K5/pTrcHis-kfoCA之间的软骨素产率,重组菌株K5/pTrcHis-kfoΔCA更适于通过发酵生产软骨素。这一结果提示可通过应用编码N-端截短的KfoC的kfoΔC基因来提高软骨素产量。
[0041]
工业实用性
通过应用本发明的细菌,可以高效且廉价地生产软骨素和硫酸软骨素。
序列表
<110>Seikagaku Corporation
<120>生产软骨素的细菌及生产软骨素的方法
<130>F200717C7102
<150>US 60/913,713
<151>2007-04-24
<160>16
<170>PatentIn version 3.3
<210>1
<211>1020
<212>DNA
<213>大肠杆菌
<220>
<221>CDS
<222>(1)..(1017)
<400>1
atg aat ata tta gtt aca ggt gga gca ggc tat att ggc tcg cat act 48
Met Asn Ile Leu Val Thr Gly Gly Ala Gly Tyr Ile Gly Ser His Thr
1 5 10 15
agt tta tgt ctt ctg aat aaa ggt tac aat gtt gta atc att gac aac 96
Ser Leu Cys Leu Leu Asn Lys Gly Tyr Asn Val Val Ile Ile Asp Asn
20 25 30
tta att aat tca tct tgc gag agc att cga agg att gaa tta ata gct 144
Leu Ile Asn Ser Ser Cys Glu Ser Ile Arg Arg Ile Glu Leu Ile Ala
35 40 45
aaa aaa aaa gtt act ttc tat gag ttg aac atc aac aat gaa aaa gaa 192
Lys Lys Lys Val Thr Phe Tyr Glu Leu Asn Ile Asn Asn Glu Lys Glu
50 55 60
gtt aat caa att cta aaa aaa cac aaa ttt gat tgt ata atg cat ttt 240
Val Asn Gln Ile Leu Lys Lys His Lys Phe Asp Cys Ile Met His Phe
65 70 75 80
gcc ggt gca aag tct gtt gct gaa tct tta ata aaa ccc att ttt tat 288
Ala Gly Ala Lys Ser Val Ala Glu Ser Leu Ile Lys Pro Ile Phe Tyr
85 90 95
tat gat aat aat gtt tca ggg acg ttg caa tta att aat tgc gct ata 336
Tyr Asp Asn Asn Val Ser Gly Thr Leu Gln Leu Ile Asn Cys Ala Ile
100 105 110
aaa aac gat gtg gct aat ttt att ttt agc tct tct gca acg gtt tat 384
Lys Asn Asp Val Ala Asn Phe Ile Phe Ser Ser Ser Ala Thr Val Tyr
115 120 125
ggt gaa agc aaa ata atg cct gta aca gaa gat tgc cat ata gga gga 432
Gly Glu Ser Lys Ile Met Pro Val Thr Glu Asp Cys His Ile Gly Gly
130 135 140
aca tta aat cca tat ggt aca tca aag tat ata tca gaa ttg atg att 480
Thr Leu Asn Pro Tyr Gly Thr Ser Lys Tyr Ile Ser Glu Leu Met Ile
145 150 155 160
aga gat att gca aaa aaa tat agc gat act aat ttt ttg tgt ctg aga 528
Arg Asp Ile Ala Lys Lys Tyr Ser Asp Thr Asn Phe Leu Cys Leu Arg
165 170 175
tat ttt aac cca aca ggt gct cac gag tcg gga atg atc ggt gaa agt 576
Tyr Phe Asn Pro Thr Gly Ala His Glu Ser Gly Met Ile Gly Glu Ser
180 185 190
ccc gct gat ata cca agc aat tta gtt cct tat ata tta caa gtt gct 624
Pro Ala Asp Ile Pro Ser Asn Leu Val Pro Tyr Ile Leu Gln Val Ala
195 200 205
atg ggt aaa cta gaa aaa ctt atg gtg ttt ggg ggg gat tac cct aca 672
Met Gly Lys Leu Glu Lys Leu Met Val Phe Gly Gly Asp Tyr Pro Thr
210 215 220
aag gat gga acc ggt gtt cgt gat tat ata cac gta atg gat tta gcg 720
Lys Asp Gly Thr Gly Val Arg Asp Tyr Ile His Val Met Asp Leu Ala
225 230 235 240
gaa ggg cat gtg gct gct tta tct tac ctt ttc cgt gat aat aac act 768
Glu Gly His Val Ala Ala Leu Ser Tyr Leu Phe Arg Asp Asn Asn Thr
245 250 255
aat tat cat gtt ttt aat tta ggt act ggt aaa gga tat tct gtt tta 816
Asn Tyr His Val Phe Asn Leu Gly Thr Gly Lys Gly Tyr Ser Val Leu
260 265 270
gag ctg gtt tct acc ttt gaa aaa ata tct ggg gtt aga att cca tat 864
Glu Leu Val Ser Thr Phe Glu Lys Ile Ser Gly Val Arg Ile Pro Tyr
275 280 285
gaa att gtt tcg aga aga gat ggg gat att gct gaa agt tgg tca tca 912
Glu Ile Val Ser Arg Arg Asp Gly Asp Ile Ala Glu Ser Trp Ser Ser
290 295 300
cca gaa aaa gca aat aag tat ctc aat tgg aaa gct aaa agg gaa ttg 960
Pro Glu Lys Ala Asn Lys Tyr Leu Asn Trp Lys Ala Lys Arg Glu Leu
305 310 315 320
gaa aca atg ctt gag gat gcc tgg cgc tgg caa atg aaa aac cca aat 1008
Glu Thr Met Leu Glu Asp Ala Trp Arg Trp Gln Met Lys Asn Pro Asn
325 330 335
ggt tat att taa 1020
Gly Tyr Ile
<210>2
<211>339
<212>PRT
<213>大肠杆菌
<400>2
Met Asn Ile Leu Val Thr Gly Gly Ala Gly Tyr Ile Gly Ser His Thr
1 5 10 15
Ser Leu Cys Leu Leu Asn Lys Gly Tyr Asn Val Val Ile Ile Asp Asn
20 25 30
Leu Ile Asn Ser Ser Cys Glu Ser Ile Arg Arg Ile Glu Leu Ile Ala
35 40 45
Lys Lys Lys Val Thr Phe Tyr Glu Leu Asn Ile Asn Asn Glu Lys Glu
50 55 60
Val Asn Gln Ile Leu Lys Lys His Lys Phe Asp Cys Ile Met His Phe
65 70 75 80
Ala Gly Ala Lys Ser Val Ala Glu Ser Leu Ile Lys Pro Ile Phe Tyr
85 90 95
Tyr Asp Asn Asn Val Ser Gly Thr Leu Gln Leu Ile Asn Cys Ala Ile
100 105 110
Lys Asn Asp Val Ala Asn Phe lle Phe Ser Ser Ser Ala Thr Val Tyr
115 120 125
Gly Glu Ser Lys Ile Met Pro Val Thr Glu Asp Cys His Ile Gly Gly
130 135 140
Thr Leu Asn Pro Tyr Gly Thr Ser Lys Tyr Ile Ser Glu Leu Met Ile
145 150 155 160
Arg Asp Ile Ala Lys Lys Tyr Ser Asp Thr Asn Phe Leu Cys Leu Arg
165 170 175
Tyr Phe Asn Pro Thr Gly Ala His Glu Ser Gly Met Ile Gly Glu Ser
180 185 190
Pro Ala Asp Ile Pro Ser Asn Leu Val Pro Tyr Ile Leu Gln Val Ala
195 200 205
Met Gly Lys Leu Glu Lys Leu Met Val Phe Gly Gly Asp Tyr Pro Thr
210 215 220
Lys Asp Gly Thr Gly Val Arg Asp Tyr Ile His Val Met Asp Leu Ala
225 230 235 240
Glu Gly His Val Ala Ala Leu Ser Tyr Leu Phe Arg Asp Asn Asn Thr
245 250 255
Asn Tyr His Val Phe Asn Leu Gly Thr Gly Lys Gly Tyr Ser Val Leu
260 265 270
Glu Leu Val Ser Thr Phe Glu Lys Ile Ser Gly Val Arg Ile Pro Tyr
275 280 285
Glu Ile Val Ser Arg Arg Asp Gly Asp Ile Ala Glu Ser Trp Ser Ser
290 295 300
Pro Glu Lys Ala Asn Lys Tyr Leu Asn Trp Lys Ala Lys Arg Glu Leu
305 310 315 320
Glu Thr Met Leu Glu Asp Ala Trp Arg Trp Gln Met Lys Asn Pro Asn
325 330 335
Gly Tyr Ile
<210>3
<211>2061
<212>DNA
<213>大肠杆菌
<220>
<221>CDS
<222>(1)..(2058)
<400>3
atg agt att ctt aat caa gca ata aat tta tat aaa aac aaa aat tat 48
Met Ser Ile Leu Asn Gln Ala Ile Asn Leu Tyr Lys Asn Lys Asn Tyr
1 5 10 15
cgc caa gct tta tct ctt ttt gag aag gtt gct gaa att tat gat gtt 96
Arg Gln Ala Leu Ser Leu Phe Glu Lys Val Ala Glu Ile Tyr Asp Val
20 25 30
agt tgg gtc gaa gca aat ata aaa tta tgc caa acc gca ctc aat ctt 144
Ser Trp Val Glu Ala Asn Ile Lys Leu Cys Gln Thr Ala Leu Asn Leu
35 40 45
tct gaa gaa gtt gat aag tta aat cgt aaa gct gtt att gat att gat 192
Ser Glu Glu Val Asp Lys Leu Asn Arg Lys Ala Val Ile Asp Ile Asp
50 55 60
gca gca aca aaa ata atg tgt tct aac gcc aaa gca att agt ctg aac 240
Ala Ala Thr Lys Ile Met Cys Ser Asn Ala Lys Ala Ile Ser Leu Asn
65 70 75 80
gag gtt gaa aaa aat gaa ata ata agc aaa tac cga gaa ata acc gca 288
Glu Val Glu Lys Asn Glu Ile Ile Ser Lys Tyr Arg Glu Ile Thr Ala
85 90 95
aag aaa tca gaa cgg gcg gag tta aag gaa gtc gaa ccc att cct tta 336
Lys Lys Ser Glu Arg Ala Glu Leu Lys Glu Val Glu Pro Ile Pro Leu
100 105 110
gat tgg cct agt gat tta act tta ccg ccg tta cct gag agc aca aac 384
Asp Trp Pro Ser Asp Leu Thr Leu Pro Pro Leu Pro Glu Ser Thr Asn
115 120 125
gat tat gtt tgg gcg ggg aaa aga aaa gag ctt gat gat tat cca aga 432
Asp Tyr Val Trp Ala Gly Lys Arg Lys Glu Leu Asp Asp Tyr Pro Arg
130 135 140
aaa cag tta atc att gac ggg ctt agt att gta att cct aca tat aat 480
Lys Gln Leu Ile Ile Asp Gly Leu Ser Ile Val Ile Pro Thr Tyr Asn
145 150 155 160
cga gca aaa ata ctt gca att aca ctt gct tgt ctt tgt aac caa aag 528
Arg Ala Lys Ile Leu Ala Ile Thr Leu Ala Cys Leu Cys Asn Gln Lys
165 170 175
acc ata tac gac tat gaa gtt att gtt gcc gat gat gga agt aaa gaa 576
Thr Ile Tyr Asp Tyr Glu Val Ile Val Ala Asp Asp Gly Ser Lys Glu
180 185 190
aat att gaa gaa ata gta aga gaa ttt gaa agt tta tta aat ata aaa 624
Asn Ile Glu Glu Ile Val Arg Glu Phe Glu Ser Leu Leu Asn Ile Lys
195 200 205
tat gta cgt cag aag gat tat gga tat caa ctg tgt gct gtt aga aat 672
Tyr Val Arg Gln Lys Asp Tyr Gly Tyr Gln Leu Cys Ala Val Arg Asn
210 215 220
ctt ggg ctt agg gct gca aag tat aat tat gtt gca att ctg gat tgt 720
Leu Gly Leu Arg Ala Ala Lys Tyr Asn Tyr Val Ala Ile Leu Asp Cys
225 230 235 240
gat atg gct ccg aac cca cta tgg gtt cag tca tat atg gaa cta tta 768
Asp Met Ala Pro Asn Pro Leu Trp Val Gln Ser Tyr Met Glu Leu Leu
245 250 255
gcg gtg gac gat aat gtt gct cta att ggc cct aga aaa tat ata gat 816
Ala Val Asp Asp Asn Val Ala Leu Ile Gly Pro Arg Lys Tyr Ile Asp
260 265 270
aca agc aag cat aca tat tta gat ttc ctt tcc caa aaa tca cta ata 864
Thr Ser Lys His Thr Tyr Leu Asp Phe Leu Ser Gln Lys Ser Leu Ile
275 280 285
aat gaa att cct gaa atc att act aat aat cag gtt gca ggc aag gtt 912
Asn Glu Ile Pro Glu Ile Ile Thr Asn Asn Gln Val Ala Gly Lys Val
290 295 300
gag caa aac aaa tca gtt gac tgg cga ata gaa cat ttc aaa aat acc 960
Glu Gln Asn Lys Ser Val Asp Trp Arg Ile Glu His Phe Lys Asn Thr
305 310 315 320
gat aat cta aga tta tgc aac aca cca ttt cga ttt ttt agc gga ggt 1008
Asp Asn Leu Arg Leu Cys Asn Thr Pro Phe Arg Phe Phe Ser Gly Gly
325 330 335
aat gtc gct ttt gcg aaa aaa tgg ctt ttc cgt gca gga tgg ttt gat 1056
Asn Val Ala Phe Ala Lys Lys Trp Leu Phe Arg Ala Gly Trp Phe Asp
340 345 350
gaa gag ttt acg cat tgg ggg ggg gag gat aat gag ttt gga tat cgt 1104
Glu Glu Phe Thr His Trp Gly Gly Glu Asp Asn Glu Phe Gly Tyr Arg
355 360 365
ctc tac aga gaa gga tgt tac ttt cgg tct gtt gaa gga gca atg gca 1152
Leu Tyr Arg Glu Gly Cys Tyr Phe Arg Ser Val Glu Gly Ala Met Ala
370 375 380
tat cat caa gaa cca ccc ggg aaa gaa aac gag acg gat cgt gcg gca 1200
Tyr His Gln Glu Pro Pro Gly Lys Glu Asn Glu Thr Asp Arg Ala Ala
385 390 395 400
ggg aaa aat att act gtt caa ttg tta cag caa aaa gtt cct tat ttc 1248
Gly Lys Asn Ile Thr Val Gln Leu Leu Gln Gln Lys Val Pro Tyr Phe
405 410 415
tat aga aaa aaa gaa aaa ata gaa tcc gcg aca tta aaa aga gta cca 1296
Tyr Arg Lys Lys Glu Lys Ile Glu Ser Ala Thr Leu Lys Arg Val Pro
420 425 430
cta gta tct ata tat att ccc gcc tat aac tgc tct aaa tat att gtt 1344
Leu Val Ser Ile Tyr Ile Pro Ala Tyr Asn Cys Ser Lys Tyr Ile Val
435 440 445
cgt tgt gtt gaa agc gcc ctt aat cag aca ata act gac tta gaa gta 1392
Arg Cys Val Glu Ser Ala Leu Asn Gln Thr Ile Thr Asp Leu Glu Val
450 455 460
tgc ata tgc gat gat ggt tcc aca gat gat aca ttg cgg att ctt cag 1440
Cys Ile Cys Asp Asp Gly Ser Thr Asp Asp Thr Leu Arg Ile Leu Gln
465 470 475 480
gag cat tat gca aac cat cct cga gtt cgt ttt att tca caa aaa aac 1488
Glu His Tyr Ala Asn His Pro Arg Val Arg Phe Ile Ser Gln Lys Asn
485 490 495
aaa gga att ggt tca gca tct aat aca gca gtt aga ttg tgt cgg gga 1536
Lys Gly Ile Gly Ser Ala Ser Asn Thr Ala Val Arg Leu Cys Arg Gly
500 505 510
ttc tat ata ggt cag tta gac tct gat gac ttt ctt gaa cca gat gct 1584
Phe Tyr Ile Gly Gln Leu Asp Ser Asp Asp Phe Leu Glu Pro Asp Ala
515 520 525
gtt gaa cta tgt cta gat gaa ttt aga aaa gat cta tca ttg gca tgt 1632
Val Glu Leu Cys Leu Asp Glu Phe Arg Lys Asp Leu Ser Leu Ala Cys
530 535 540
gtt tat aca act aac cgt aat ata gat cgt gaa ggt aat ttg ata tca 1680
Val Tyr Thr Thr Asn Arg Asn Ile Asp Arg Glu Gly Asn Leu Ile Ser
545 550 555 560
aat ggc tat aat tgg ccc att tat tcg cga gaa aaa ctt act agt gca 1728
Asn Gly Tyr Asn Trp Pro Ile Tyr Ser Arg Glu Lys Leu Thr Ser Ala
565 570 575
atg ata tgt cat cat ttc agg atg ttc aca gca aga gca tgg aac cta 1776
Met Ile Cys His His Phe Arg Met Phe Thr Ala Arg Ala Trp Asn Leu
580 585 590
act gaa ggt ttc aac gaa tcg atc agc aac gca gtt gat tac gat atg 1824
Thr Glu Gly Phe Asn Glu Ser Ile Ser Asn Ala Val Asp Tyr Asp Met
595 600 605
tat tta aaa ctt agt gaa gtt gga ccg ttc aag cat ata aac aaa att 1872
Tyr Leu Lys Leu Ser Glu Val Gly Pro Phe Lys His Ile Asn Lys Ile
610 615 620
tgt tat aat cgc gta ttg cat ggt gaa aat acg tct ata aaa aag ttg 1920
Cys Tyr Asn Arg Val Leu His Gly Glu Asn Thr Ser Ile Lys Lys Leu
625 630 635 640
gat att caa aag gaa aat cat ttt aaa gtt gtt aac gaa tca tta agt 1968
Asp Ile Gln Lys Glu Asn His Phe Lys Val Val Asn Glu Ser Leu Ser
645 650 655
agg cta ggc ata aaa aaa tat aaa tat tca cca tta act aat ttg aat 2016
Arg Leu Gly Ile Lys Lys Tyr Lys Tyr Ser Pro Leu Thr Asn Leu Asn
660 665 670
gaa tgt aga aaa tat acc tgg gaa aaa ata gag aat gat tta taa 2061
Glu Cys Arg Lys Tyr Thr Trp Glu Lys Ile Glu Asn Asp Leu
675 680 685
<210>4
<211>686
<212>PRT
<213>大肠杆菌
<400>4
Met Ser Ile Leu Asn Gln Ala Ile Asn Leu Tyr Lys Asn Lys Asn Tyr
1 5 10 15
Arg Gln Ala Leu Ser Leu Phe Glu Lys Val Ala Glu Ile Tyr Asp Val
20 25 30
Ser Trp Val Glu Ala Asn Ile Lys Leu Cys Gln Thr Ala Leu Asn Leu
35 40 45
Ser Glu Glu Val Asp Lys Leu Asn Arg Lys Ala Val Ile Asp Ile Asp
50 55 60
Ala Ala Thr Lys Ile Met Cys Ser Asn Ala Lys Ala Ile Ser Leu Asn
65 70 75 80
Glu Val Glu Lys Asn Glu Ile Ile Ser Lys Tyr Arg Glu Ile Thr Ala
85 90 95
Lys Lys Ser Glu Arg Ala Glu Leu Lys Glu Val Glu Pro Ile Pro Leu
100 105 110
Asp Trp Pro Ser Asp Leu Thr Leu Pro Pro Leu Pro Glu Ser Thr Asn
115 120 125
Asp Tyr Val Trp Ala Gly Lys Arg Lys Glu Leu Asp Asp Tyr Pro Arg
130 135 140
Lys Gln Leu Ile Ile Asp Gly Leu Ser Ile Val Ile Pro Thr Tyr Asn
145 150 155 160
Arg Ala Lys Ile Leu Ala Ile Thr Leu Ala Cys Leu Cys Asn Gln Lys
165 170 175
Thr Ile Tyr Asp Tyr Glu Val Ile Val Ala Asp Asp Gly Ser Lys Glu
180 185 190
Asn Ile Glu Glu Ile Val Arg Glu Phe Glu Ser Leu Leu Asn Ile Lys
195 200 205
Tyr Val Arg Gln Lys Asp Tyr Gly Tyr Gln Leu Cys Ala Val Arg Asn
210 215 220
Leu Gly Leu Arg Ala Ala Lys Tyr Asn Tyr Val Ala Ile Leu Asp Cys
225 230 235 240
Asp Met Ala Pro Asn Pro Leu Trp Val Gln Ser Tyr Met Glu Leu Leu
245 250 255
Ala Val Asp Asp Asn Val Ala Leu Ile Gly Pro Arg Lys Tyr Ile Asp
260 265 270
Thr Ser Lys His Thr Tyr Leu Asp Phe Leu Ser Gln Lys Ser Leu Ile
275 280 285
Asn Glu Ile Pro Glu Ile Ile Thr Asn Asn Gln Val Ala Gly Lys Val
290 295 300
Glu Gln Asn Lys Ser Val Asp Trp Arg Ile Glu His Phe Lys Asn Thr
305 310 315 320
Asp Asn Leu Arg Leu Cys Asn Thr Pro Phe Arg Phe Phe Ser Gly Gly
325 330 335
Asn Val Ala Phe Ala Lys Lys Trp Leu Phe Arg Ala Gly Trp Phe Asp
340 345 350
Glu Glu Phe Thr His Trp Gly Gly Glu Asp Asn Glu Phe Gly Tyr Arg
355 360 365
Leu Tyr Arg Glu Gly Cys Tyr Phe Arg Ser Val Glu Gly Ala Met Ala
370 375 380
Tyr His Gln Glu Pro Pro Gly Lys Glu Asn Glu Thr Asp Arg Ala Ala
385 390 395 400
Gly Lys Asn Ile Thr Val Gln Leu Leu Gln Gln Lys Val Pro Tyr Phe
405 410 415
Tyr Arg Lys Lys Glu Lys Ile Glu Ser Ala Thr Leu Lys Arg Val Pro
420 425 430
Leu Val Ser Ile Tyr Ile Pro Ala Tyr Asn Cys Ser Lys Tyr Ile Val
435 440 445
Arg Cys Val Glu Ser Ala Leu Asn Gln Thr Ile Thr Asp Leu Glu Val
450 455 460
Cys Ile Cys Asp Asp Gly Ser Thr Asp Asp Thr Leu Arg Ile Leu Gln
465 470 475 480
Glu His Tyr Ala Asn His Pro Arg Val Arg Phe Ile Ser Gln Lys Asn
485 490 495
Lys Gly Ile Gly Ser Ala Ser Asn Thr Ala Val Arg Leu Cys Arg Gly
500 505 510
Phe Tyr Ile Gly Gln Leu Asp Ser Asp Asp Phe Leu Glu Pro Asp Ala
515 520 525
Val Glu Leu Cys Leu Asp Glu Phe Arg Lys Asp Leu Ser Leu Ala Cys
530 535 540
Val Tyr Thr Thr Asn Arg Asn Ile Asp Arg Glu Gly Asn Leu Ile Ser
545 550 555 560
Asn Gly Tyr Asn Trp Pro Ile Tyr Ser Arg Glu Lys Leu Thr Ser Ala
565 570 575
Met Ile Cys His His Phe Arg Met Phe Thr Ala Arg Ala Trp Asn Leu
580 585 590
Thr Glu Gly Phe Asn Glu Ser Ile Ser Asn Ala Val Asp Tyr Asp Met
595 600 605
Tyr Leu Lys Leu Ser Glu Val Gly Pro Phe Lys His Ile Asn Lys Ile
610 615 620
Cys Tyr Asn Arg Val Leu His Gly Glu Asn Thr Ser Ile Lys Lys Leu
625 630 635 640
Asp Ile Gln Lys Glu Asn His Phe Lys Val Val Asn Glu Ser Leu Ser
645 650 655
Arg Leu Gly Ile Lys Lys Tyr Lys Tyr Ser Pro Leu Thr Asn Leu Asn
660 665 670
Glu Cys Arg Lys Tyr Thr Trp Glu Lys Ile Glu Asn Asp Leu
675 680 685
<210>5
<211>1890
<212>DNA
<213>大肠杆菌
<220>
<221>CDS
<222>(1)..(1887)
<400>5
aaa gct gtt att gat att gat gca gca aca aaa ata atg tgt tct aac 48
Lys Ala Val Ile Asp Ile Asp Ala Ala Thr Lys Ile Met Cys Ser Asn
1 5 10 15
gcc aaa gca att agt ctg aac gag gtt gaa aaa aat gaa ata ata agc 96
Ala Lys Ala Ile Ser Leu Asn Glu Val Glu Lys Asn Glu Ile Ile Ser
20 25 30
aaa tac cga gaa ata acc gca aag aaa tca gaa cgg gcg gag tta aag 144
Lys Tyr Arg Glu Ile Thr Ala Lys Lys Ser Glu Arg Ala Glu Leu Lys
35 40 45
gaa gtc gaa ccc att cct tta gat tgg cct agt gat tta act tta ccg 192
Glu Val Glu Pro Ile Pro Leu Asp Trp Pro Ser Asp Leu Thr Leu Pro
50 55 60
ccg tta cct gag agc aca aac gat tat gtt tgg gcg ggg aaa aga aaa 240
Pro Leu Pro Glu Ser Thr Asn Asp Tyr Val Trp Ala Gly Lys Arg Lys
65 70 75 80
gag ctt gat gat tat cca aga aaa cag tta atc att gac ggg ctt agt 288
Glu Leu Asp Asp Tyr Pro Arg Lys Gln Leu Ile Ile Asp Gly Leu Ser
85 90 95
att gta att cct aca tat aat cga gca aaa ata ctt gca att aca ctt 336
Ile Val Ile Pro Thr Tyr Asn Arg Ala Lys Ile Leu Ala Ile Thr Leu
100 105 110
gct tgt ctt tgt aac caa aag acc ata tac gac tat gaa gtt att gtt 384
Ala Cys Leu Cys Asn Gln Lys Thr Ile Tyr Asp Tyr Glu ValIle Val
115 120 125
gcc gat gat gga agt aaa gaa aat att gaa gaa ata gta aga gaa ttt 432
Ala Asp Asp Gly Ser Lys Glu Asn Ile Glu Glu Ile Val Arg Glu Phe
130 135 140
gaa agt tta tta aat ata aaa tat gta cgt cag aag gat tat gga tat 480
Glu Ser Leu Leu Asn Ile Lys Tyr Val Arg Gln Lys Asp Tyr Gly Tyr
145 150 155 160
caa ctg tgt gct gtt aga aat ctt ggg ctt agg gct gca aag tat aat 528
Gln Leu Cys Ala Val Arg Asn Leu Gly Leu Arg Ala Ala Lys Tyr Asn
165 170 175
tat gtt gca att ctg gat tgt gat atg gct ccg aac cca cta tgg gtt 576
Tyr Val Ala Ile Leu Asp Cys Asp Met Ala Pro Asn Pro Leu Trp Val
180 185 190
cag tca tat atg gaa cta tta gcg gtg gac gat aat gtt gct cta att 624
Gln Ser Tyr Met Glu Leu Leu Ala Val Asp Asp Asn Val Ala Leu Ile
195 200 205
ggc cct aga aaa tat ata gat aca agc aag cat aca tat tta gat ttc 672
Gly Pro Arg Lys Tyr Ile Asp Thr Ser Lys His Thr Tyr Leu Asp Phe
210 215 220
ctt tcc caa aaa tca cta ata aat gaa att cct gaa atc att act aat 720
Leu Ser Gln Lys Ser Leu Ile Asn Glu Ile Pro Glu Ile Ile Thr Asn
225 230 235 240
aat cag gtt gca ggc aag gtt gag caa aac aaa tca gtt gac tgg cga 768
Asn Gln Val Ala Gly Lys Val Glu Gln Asn Lys Ser Val Asp Trp Arg
245 250 255
ata gaa cat ttc aaa aat acc gat aat cta aga tta tgc aac aca cca 816
Ile Glu His Phe Lys Asn Thr Asp Asn Leu Arg Leu Cys Asn Thr Pro
260 265 270
ttt cga ttt ttt agc gga ggt aat gtc gct ttt gcg aaa aaa tgg ctt 864
Phe Arg Phe Phe Ser Gly Gly Asn Val Ala Phe Ala Lys Lys Trp Leu
275 280 285
ttc cgt gca gga tgg ttt gat gaa gag ttt acg cat tgg ggg ggg gag 912
Phe Arg Ala Gly Trp Phe Asp Glu Glu Phe Thr His Trp Gly Gly Glu
290 295 300
gat aat gag ttt gga tat cgt ctc tac aga gaa gga tgt tac ttt cgg 960
Asp Asn Glu Phe Gly Tyr Arg Leu Tyr Arg Glu Gly Cys Tyr Phe Arg
305 310 315 320
tct gtt gaa gga gca atg gca tat cat caa gaa cca ccc ggg aaa gaa 1008
Ser Val Glu Gly Ala Met Ala Tyr His Gln Glu Pro Pro Gly Lys Glu
325 330 335
aac gag acg gat cgt gcg gca ggg aaa aat att act gtt caa ttg tta 1056
Asn Glu Thr Asp Arg Ala Ala Gly Lys Asn Ile Thr Val Gln Leu Leu
340 345 350
cag caa aaa gtt cct tat ttc tat aga aaa aaa gaa aaa ata gaa tcc 1104
Gln Gln Lys Val Pro Tyr Phe Tyr Arg Lys Lys Glu Lys Ile Glu Ser
355 360 365
gcg aca tta aaa aga gta cca cta gta tct ata tat att ccc gcc tat 1152
Ala Thr Leu Lys Arg Val Pro Leu Val Ser Ile Tyr Ile Pro Ala Tyr
370 375 380
aac tgc tct aaa tat att gtt cgt tgt gtt gaa agc gcc ctt aat cag 1200
Asn Cys Ser Lys Tyr Ile Val Arg Cys Val Glu Ser Ala Leu Asn Gln
385 390 395 400
aca ata act gac tta gaa gta tgc ata tgc gat gat ggt tcc aca gat 1248
Thr Ile Thr Asp Leu Glu Val Cys Ile Cys Asp Asp Gly Ser Thr Asp
405 410 415
gat aca ttg cgg att ctt cag gag cat tat gca aac cat cct cga gtt 1296
Asp Thr Leu Arg Ile Leu Gln Glu His Tyr Ala Asn His Pro Arg Val
420 425 430
cgt ttt att tca caa aaa aac aaa gga att ggt tca gca tct aat aca 1344
Arg Phe Ile Ser Gln Lys Asn Lys Gly Ile Gly Ser Ala Ser Asn Thr
435 440 445
gca gtt aga ttg tgt cgg gga ttc tat ata ggt cag tta gac tct gat 1392
Ala Val Arg Leu Cys Arg Gly Phe Tyr Ile Gly Gln Leu Asp Ser Asp
450 455 460
gac ttt ctt gaa cca gat gct gtt gaa cta tgt cta gat gaa ttt aga 1440
Asp Phe Leu Glu Pro Asp Ala Val Glu Leu Cys Leu Asp Glu Phe Arg
465 470 475 480
aaa gat cta tca ttg gca tgt gtt tat aca act aac cgt aat ata gat 1488
Lys Asp Leu Ser Leu Ala Cys Val Tyr Thr Thr Asn Arg Asn Ile Asp
485 490 495
cgt gaa ggt aat ttg ata tca aat ggc tat aat tgg ccc att tat tcg 1536
Arg Glu Gly Asn Leu Ile Ser Asn Gly Tyr Asn Trp Pro Ile Tyr Ser
500 505 510
cga gaa aaa ctt act agt gca atg ata tgt cat cat ttc agg atg ttc 1584
Arg Glu Lys Leu Thr Ser Ala Met Ile Cys His His Phe Arg Met Phe
515 520 525
aca gca aga gca tgg aac cta act gaa ggt ttc aac gaa tcg atc agc 1632
Thr Ala Arg Ala Trp Asn Leu Thr Glu Gly Phe Asn Glu Ser Ile Ser
530 535 540
aac gca gtt gat tac gat atg tat tta aaa ctt agt gaa gtt gga ccg 1680
Asn Ala Val Asp Tyr Asp Met Tyr Leu Lys Leu Ser Glu Val Gly Pro
545 550 555 560
ttc aag cat ata aac aaa att tgt tat aat cgc gta ttg cat ggt gaa 1728
Phe Lys His Ile Asn Lys Ile Cys Tyr Asn Arg Val Leu His Gly Glu
565 570 575
aat acg tct ata aaa aag ttg gat att caa aag gaa aat cat ttt aaa 1776
Asn Thr Ser Ile Lys Lys Leu Asp Ile Gln Lys Glu Asn His Phe Lys
580 585 590
gtt gtt aac gaa tca tta agt agg cta ggc ata aaa aaa tat aaa tat 1824
Val Val Asn Glu Ser Leu Ser Arg Leu Gly Ile Lys Lys Tyr Lys Tyr
595 600 605
tca cca tta act aat ttg aat gaa tgt aga aaa tat acc tgg gaa aaa 1872
Ser Pro Leu Thr Asn Leu Asn Glu Cys Arg Lys Tyr Thr Trp Glu Lys
610 615 620
ata gag aat gat tta taa 1890
Ile Glu Asn Asp Leu
625
<210>6
<211>629
<212>PRT
<213>大肠杆菌
<400>6
Lys Ala Val Ile Asp Ile Asp Ala Ala Thr Lys Ile Met Cys Ser Asn
1 5 10 15
Ala Lys Ala Ile Ser Leu Asn Glu Val Glu Lys Asn Glu Ile Ile Ser
20 25 30
Lys Tyr Arg Glu Ile Thr Ala Lys Lys Ser Glu Arg Ala Glu Leu Lys
35 40 45
Glu Val Glu Pro Ile Pro Leu Asp Trp Pro Ser Asp Leu Thr Leu Pro
50 55 60
Pro Leu Pro Glu Ser Thr Asn Asp Tyr Val Trp Ala Gly Lys Arg Lys
65 70 75 80
Glu Leu Asp Asp Tyr Pro Arg Lys Gln Leu Ile Ile Asp Gly Leu Ser
85 90 95
Ile Val Ile Pro Thr Tyr Asn Arg Ala Lys Ile Leu Ala Ile Thr Leu
100 105 110
Ala Cys Leu Cys Asn Gln Lys Thr Ile Tyr Asp Tyr Glu Val Ile Val
115 120 125
Ala Asp Asp Gly Ser Lys Glu Asn Ile Glu Glu Ile Val Arg Glu Phe
130 135 140
Glu Ser Leu Leu Asn Ile Lys Tyr Val Arg Gln Lys Asp Tyr Gly Tyr
145 150 155 160
Gln Leu Cys Ala Val Arg Asn Leu Gly Leu Arg Ala Ala Lys Tyr Asn
165 170 175
Tyr Val Ala Ile Leu Asp Cys Asp Met Ala Pro Asn Pro Leu Trp Val
180 185 190
Gln Ser Tyr Met Glu Leu Leu Ala Val Asp Asp Asn Val Ala Leu Ile
195 200 205
Gly Pro Arg Lys Tyr Ile Asp Thr Ser Lys His Thr Tyr Leu Asp Phe
210 215 220
Leu Ser Gln Lys Ser Leu Ile Asn Glu Ile Pro Glu Ile Ile Thr Asn
225 230 235 240
Asn Gln Val Ala Gly Lys Val Glu Gln Asn Lys Ser Val Asp Trp Arg
245 250 255
Ile Glu His Phe Lys Asn Thr Asp Asn Leu Arg Leu Cys Asn Thr Pro
260 265 270
Phe Arg Phe Phe Ser Gly Gly Asn Val Ala Phe Ala Lys Lys Trp Leu
275 280 285
Phe Arg Ala Gly Trp Phe Asp Glu Glu Phe Thr His Trp Gly Gly Glu
290 295 300
Asp Asn Glu Phe Gly Tyr Arg Leu Tyr Arg Glu Gly Cys Tyr Phe Arg
305 310 315 320
Ser Val Glu Gly Ala Met Ala Tyr His Gln Glu Pro Pro Gly Lys Glu
325 330 335
Asn Glu Thr Asp Arg Ala Ala Gly Lys Asn Ile Thr Val Gln Leu Leu
340 345 350
Gln Gln Lys Val Pro Tyr Phe Tyr Arg Lys Lys Glu Lys Ile Glu Ser
355 360 365
Ala Thr Leu Lys Arg Val Pro Leu Val Ser Ile Tyr Ile Pro Ala Tyr
370 375 380
Asn Cys Ser Lys Tyr Ile Val Arg Cys Val Glu Ser Ala Leu Asn Gln
385 390 395 400
Thr Ile Thr Asp Leu Glu Val Cys Ile Cys Asp Asp Gly Ser Thr Asp
405 410 415
Asp Thr Leu Arg Ile Leu Gln Glu His Tyr Ala Asn His Pro Arg Val
420 425 430
Arg Phe Ile Ser Gln Lys Asn Lys Gly Ile Gly Ser Ala Ser Asn Thr
435 440 445
Ala Val Arg Leu Cys Arg Gly Phe Tyr Ile Gly Gln Leu Asp Ser Asp
450 455 460
Asp Phe Leu Glu Pro Asp Ala Val Glu Leu Cys Leu Asp Glu Phe Arg
465 470 475 480
Lys Asp Leu Ser Leu Ala Cys Val Tyr Thr Thr Asn Arg Asn Ile Asp
485 490 495
Arg Glu Gly Asn Leu Ile Ser Asn Gly Tyr Asn Trp Pro Ile Tyr Ser
500 505 510
Arg Glu Lys Leu Thr Ser Ala Met Ile Cys His His Phe Arg Met Phe
515 520 525
Thr Ala Arg Ala Trp Asn Leu Thr Glu Gly Phe Asn Glu Ser Ile Ser
530 535 540
Asn Ala Val Asp Tyr Asp Met Tyr Leu Lys Leu Ser Glu Val Gly Pro
545 550 555 560
Phe Lys His Ile Asn Lys Ile Cys Tyr Asn Arg Val Leu His Gly Glu
565 570 575
Asn Thr Ser Ile Lys Lys Leu Asp Ile Gln Lys Glu Asn His Phe Lys
580 585 590
Val Val Asn Glu Ser Leu Ser Arg Leu Gly Ile Lys Lys Tyr Lys Tyr
595 600 605
Ser Pro Leu Thr Asn Leu Asn Glu Cys Arg Lys Tyr Thr Trp Glu Lys
610 615 620
Ile Glu Asn Asp Leu
625
<210>7
<211>30
<212>DNA
<213>人工序列
<220>
<223>引物
<400>7
cgggatcccg atgagtattc ttaatcaagc 30
<210>8
<211>30
<212>DNA
<213>人工序列
<220>
<223>引物
<400>8
ggaattccgg ccagtctaca tgtttatcac 30
<210>9
<211>30
<212>DNA
<213>人工序列
<220>
<223>引物
<400>9
cgggatcccg atgagtattc ttaatcaagc 30
<210>10
<211>30
<212>DNA
<213>人工序列
<220>
<223>引物
<400>10
ggaattccgg ccagtctaca tgtttatcac 30
<210>11
<211>30
<212>DNA
<213>人工序列
<220>
<223>引物
<400>11
gcggccgcaa aacagccaag cttcgaattc 30
<210>12
<211>32
<212>DNA
<213>人工序列
<220>
<223>引物
<400>12
acgcgtcgac ggcggatgag agaagatttt ca 32
<210>13
<211>39
<212>DNA
<213>人工序列
<220>
<223>引物
<400>13
gcggccgcaa aattaaagag gtatatatta atgtatcga 39
<210>14
<211>24
<212>DNA
<213>人工序列
<220>
<223>引物
<400>14
gtcgacctct catccgccaa aaca 24
<210>15
<211>22
<212>PRT
<213>人工序列e
<220>
<223>KfoA的部分肽
<400>15
Cys Ile Val Ser Arg Arg Asp Gly Asp Ile Ala Glu Ser Trp Ser Ser
1 5 10 15
Pro Glu Lys Ala Asn Lys
20
<210>16
<211>17
<212>PRT
<213>人工序列
<220>
<223>KfoC的部分肽
<400>16
Cys Gln Glu Pro Pro Gly Lys Glu Asn Glu Thr Asp Arg Ala Ala Gly
1 5 10 15
Lys
Claims (11)
1.产生UDP-葡糖醛酸的细菌,为该细菌引入了衍生自大肠杆菌K4株的kfoA基因和衍生自大肠杆菌K4株的kfoC基因,并且所述细菌具有产生软骨素的能力。
2.根据权利要求1的细菌,其中所述的kfoA基因编码选自由以下(A)和(B)所组成的组的蛋白质:
(A)包含SEQ ID NO:2氨基酸序列的蛋白质;以及
(B)包含SEQ ID NO:2氨基酸序列的蛋白质,其包括一个或几个氨基酸的替换、缺失、插入或添加并具有UDP-葡萄糖-4-差向异构酶活性。
3.根据权利要求1的细菌,其中所述的kfoA基因是选自由以下(a)和(b)组成的组的DNA:
(a)包含SEQ ID NO:1的核苷酸序列的DNA;和
(b)在严格条件下与包含和SEQ ID NO:1互补的核苷酸序列的DNA杂交并编码具有UDP-葡萄糖-4-差向异构酶活性的蛋白的DNA。
4.根据权利要求1至3任一项的细菌,其中所述的kfoC基因编码选自由以下(C)和(D)所组成的组的蛋白:
(C)包含SEQ ID NO:4的氨基酸序列的蛋白质;以及
(D)包含SEQ ID NO:4的氨基酸序列的蛋白质,其包括一个或几个氨基酸的替换、缺失、插入或添加并具有软骨素合酶活性。
5.根据权利要求1至3中任一项的细菌,其中所述的kfoC基因是选自由以下(c)和(d)组成的组的DNA:
(c)包含SEQ ID NO:3的核苷酸序列的DNA;和
(d)在严格条件下与包含和SEQ ID NO:3互补的核苷酸序列的DNA杂交并编码具有软骨素合酶活性的蛋白的DNA。
6.根据权利要求1至3中任一项的细菌,其中所述的kfoC基因编码选自由以下(E)和(F)所组成的组的蛋白:
(E)包含SEQ ID NO:6氨基酸序列的蛋白质;以及
(F)包含SEQ ID NO:6氨基酸序列的蛋白质,其包括一个或几个氨基酸的替换、缺失、插入或添加并具有软骨素合酶活性。
7.根据权利要求1至3中任一项的细菌,其中所述的kfoC基因是选自由以下(e)和(f)组成的组的DNA:
(e)包含SEQ ID NO:5的核苷酸序列的DNA;和
(f)在严格条件下与包含和SEQ ID NO:5互补的核苷酸序列的DNA杂交并编码具有软骨素合酶活性之蛋白的DNA。
8.根据权利要求1至7中任一项的细菌,其中所述的细菌是大肠杆菌K5菌株。
9.生产软骨素的方法,其至少包括以下步骤(1)和(2):
(1)培养根据权利要求1至7中任一项的细菌;以及
(2)从该培养物中收集软骨素。
10.生产硫酸软骨素的方法,其包括:通过根据权利要求9的方法生产软骨素;以及将所述软骨素硫酸化以产生硫酸软骨素。
11.包含衍生自大肠杆菌K4株的kfoA基因和衍生自大肠杆菌K4株的kfoC基因的载体。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510312412.3A CN104974973B (zh) | 2007-04-24 | 2008-04-24 | 生产软骨素的细菌及生产软骨素的方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91371307P | 2007-04-24 | 2007-04-24 | |
US60/913,713 | 2007-04-24 | ||
PCT/JP2008/058323 WO2008133350A1 (en) | 2007-04-24 | 2008-04-24 | Chondroitin-producing bacterium and method of producing chondroitin |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510312412.3A Division CN104974973B (zh) | 2007-04-24 | 2008-04-24 | 生产软骨素的细菌及生产软骨素的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101679955A true CN101679955A (zh) | 2010-03-24 |
CN101679955B CN101679955B (zh) | 2015-06-17 |
Family
ID=39683971
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880013071.8A Expired - Fee Related CN101679955B (zh) | 2007-04-24 | 2008-04-24 | 生产软骨素的细菌及生产软骨素的方法 |
CN201510312412.3A Active CN104974973B (zh) | 2007-04-24 | 2008-04-24 | 生产软骨素的细菌及生产软骨素的方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510312412.3A Active CN104974973B (zh) | 2007-04-24 | 2008-04-24 | 生产软骨素的细菌及生产软骨素的方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US8283145B2 (zh) |
EP (1) | EP2142643B1 (zh) |
JP (1) | JP5393481B2 (zh) |
KR (1) | KR101548139B1 (zh) |
CN (2) | CN101679955B (zh) |
CA (1) | CA2684883C (zh) |
ES (1) | ES2650799T3 (zh) |
WO (1) | WO2008133350A1 (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102459625A (zh) * | 2009-05-25 | 2012-05-16 | 阿尔特刚股份有限公司 | 生物技术生产软骨素 |
CN102618597A (zh) * | 2012-04-06 | 2012-08-01 | 江南大学 | 大肠杆菌工程菌及其生产软骨素的方法 |
CN102965414A (zh) * | 2012-11-27 | 2013-03-13 | 江南大学 | 一种发酵液中提取硫酸软骨素的方法 |
CN103635491A (zh) * | 2011-05-20 | 2014-03-12 | 灵知股份公司 | 类鲨鱼硫酸软骨素及其制备方法 |
CN104328073A (zh) * | 2014-10-30 | 2015-02-04 | 江南大学 | 一株产游离葡萄糖醛酸的木糖葡糖醋杆菌 |
CN104388372A (zh) * | 2014-12-04 | 2015-03-04 | 江南大学 | 一种产软骨素的重组枯草芽孢杆菌及其应用 |
CN104974972A (zh) * | 2010-07-09 | 2015-10-14 | 灵知股份公司 | 软骨素的生物技术制备 |
CN106244566A (zh) * | 2016-08-10 | 2016-12-21 | 江南大学 | 一种软骨素合酶突变体及其应用 |
CN111954713A (zh) * | 2018-03-05 | 2020-11-17 | 科纳根公司 | 用于产生具有低硫酸化的糖分子的生物体和方法 |
CN112708569A (zh) * | 2019-10-24 | 2021-04-27 | 华熙生物科技股份有限公司 | 发酵生产硫酸软骨素的酵母工程菌及其应用 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8431226B2 (en) * | 2005-03-30 | 2013-04-30 | Biomet Manufacturing Corp. | Coated medical device |
KR101443052B1 (ko) | 2006-06-12 | 2014-09-22 | 세이가가쿠 고교 가부시키가이샤 | 변형된 콘드로이틴 합성 효소 폴리펩타이드 및 이의 결정 |
ES2661593T3 (es) | 2010-03-01 | 2018-04-02 | Seikagaku Corporation | Composiciones y métodos para producción bacteriana de condroitina |
ITMI20101300A1 (it) * | 2010-07-15 | 2012-01-15 | Gnosis Spa | Produzione biotecnologica di condroitina |
ITMI20101264A1 (it) * | 2010-07-09 | 2012-01-09 | Gnosis Spa | Produzione biotecnologica di condroitina |
US8664196B2 (en) | 2011-05-20 | 2014-03-04 | Gnosis S.P.A. | Shark-like chondroitin sulphate and process for the preparation thereof |
JP6478115B2 (ja) | 2013-09-30 | 2019-03-06 | 生化学工業株式会社 | タンパク質の血中滞留性の増強方法 |
CN106497845B (zh) * | 2016-12-14 | 2019-08-06 | 江南大学 | 一种高产软骨素的重组枯草芽孢杆菌及其应用 |
CN108841771B (zh) * | 2018-07-11 | 2020-12-01 | 江南大学 | 一种产软骨素的重组谷氨酸棒杆菌及其应用 |
EP4067487A1 (en) | 2021-04-01 | 2022-10-05 | Givaudan SA | Chondroitin-producing recombinant cell |
CN118005821B (zh) * | 2024-02-22 | 2024-08-06 | 元朵(上海)科技有限公司 | 基于微生物发酵的硫酸软骨素及其高产量提取方法、应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0699485B2 (ja) | 1984-08-14 | 1994-12-07 | 生化学工業株式会社 | 合成コンドロイチン多硫酸の製造法 |
JP4059565B2 (ja) | 1998-06-23 | 2008-03-12 | 生化学工業株式会社 | 新規硫酸基転移酵素 |
US7642071B2 (en) * | 1999-04-01 | 2010-01-05 | The Board Of Regents Of The University Of Oklahoma | Methods of expressing gram-negative glycosaminoglycan synthase genes in gram-positive hosts |
JP2004512013A (ja) * | 2000-04-25 | 2004-04-22 | デ アンジェリス,ポール,エル. | コンドロイチンシンターゼ遺伝子並びにその生成方法及び使用方法 |
JP4101548B2 (ja) | 2001-08-10 | 2008-06-18 | 生化学工業株式会社 | コンドロイチン合成酵素及びそれをコードするdna |
WO2003102194A1 (fr) | 2002-05-31 | 2003-12-11 | Seikagaku Corporation | Chondroitine synthetase et codage de l'adn pour l'enzyme |
ATE388233T1 (de) | 2002-05-31 | 2008-03-15 | Seikagaku Kogyo Co Ltd | Chondroitinsynthetase und das enzym codierende nukleinsäure |
WO2007023867A1 (ja) | 2005-08-24 | 2007-03-01 | Seikagaku Corporation | 新規コンドロイチン画分製造方法 |
US8067204B2 (en) | 2005-12-15 | 2011-11-29 | Seikagaku Corporation | Long-chain chondroitin sugar chain and method for producing the same and method for promoting synthesis of chondroitin |
KR101443052B1 (ko) | 2006-06-12 | 2014-09-22 | 세이가가쿠 고교 가부시키가이샤 | 변형된 콘드로이틴 합성 효소 폴리펩타이드 및 이의 결정 |
-
2008
- 2008-04-24 US US12/596,980 patent/US8283145B2/en active Active
- 2008-04-24 JP JP2009545755A patent/JP5393481B2/ja active Active
- 2008-04-24 ES ES08740988.4T patent/ES2650799T3/es active Active
- 2008-04-24 CN CN200880013071.8A patent/CN101679955B/zh not_active Expired - Fee Related
- 2008-04-24 CN CN201510312412.3A patent/CN104974973B/zh active Active
- 2008-04-24 WO PCT/JP2008/058323 patent/WO2008133350A1/en active Application Filing
- 2008-04-24 CA CA2684883A patent/CA2684883C/en active Active
- 2008-04-24 KR KR1020097024438A patent/KR101548139B1/ko active IP Right Grant
- 2008-04-24 EP EP08740988.4A patent/EP2142643B1/en active Active
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102459625B (zh) * | 2009-05-25 | 2015-02-11 | 阿尔特刚股份有限公司 | 生物技术生产软骨素 |
CN102459625A (zh) * | 2009-05-25 | 2012-05-16 | 阿尔特刚股份有限公司 | 生物技术生产软骨素 |
CN104974972A (zh) * | 2010-07-09 | 2015-10-14 | 灵知股份公司 | 软骨素的生物技术制备 |
CN103635491A (zh) * | 2011-05-20 | 2014-03-12 | 灵知股份公司 | 类鲨鱼硫酸软骨素及其制备方法 |
CN102618597A (zh) * | 2012-04-06 | 2012-08-01 | 江南大学 | 大肠杆菌工程菌及其生产软骨素的方法 |
CN102965414A (zh) * | 2012-11-27 | 2013-03-13 | 江南大学 | 一种发酵液中提取硫酸软骨素的方法 |
CN104328073A (zh) * | 2014-10-30 | 2015-02-04 | 江南大学 | 一株产游离葡萄糖醛酸的木糖葡糖醋杆菌 |
CN104388372A (zh) * | 2014-12-04 | 2015-03-04 | 江南大学 | 一种产软骨素的重组枯草芽孢杆菌及其应用 |
CN104388372B (zh) * | 2014-12-04 | 2017-07-21 | 江南大学 | 一种产软骨素的重组枯草芽孢杆菌及其应用 |
CN106244566A (zh) * | 2016-08-10 | 2016-12-21 | 江南大学 | 一种软骨素合酶突变体及其应用 |
CN106244566B (zh) * | 2016-08-10 | 2019-08-20 | 江南大学 | 一种软骨素合酶突变体及其应用 |
CN111954713A (zh) * | 2018-03-05 | 2020-11-17 | 科纳根公司 | 用于产生具有低硫酸化的糖分子的生物体和方法 |
CN112708569A (zh) * | 2019-10-24 | 2021-04-27 | 华熙生物科技股份有限公司 | 发酵生产硫酸软骨素的酵母工程菌及其应用 |
CN112708569B (zh) * | 2019-10-24 | 2022-11-01 | 华熙生物科技股份有限公司 | 发酵生产硫酸软骨素的酵母工程菌及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CA2684883C (en) | 2016-06-21 |
JP5393481B2 (ja) | 2014-01-22 |
KR101548139B1 (ko) | 2015-08-28 |
CN104974973A (zh) | 2015-10-14 |
ES2650799T3 (es) | 2018-01-22 |
WO2008133350A1 (en) | 2008-11-06 |
EP2142643B1 (en) | 2017-11-01 |
CA2684883A1 (en) | 2008-11-06 |
KR20100017307A (ko) | 2010-02-16 |
CN104974973B (zh) | 2022-07-26 |
EP2142643A1 (en) | 2010-01-13 |
CN101679955B (zh) | 2015-06-17 |
JP2010524431A (ja) | 2010-07-22 |
US8283145B2 (en) | 2012-10-09 |
US20100151532A1 (en) | 2010-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101679955B (zh) | 生产软骨素的细菌及生产软骨素的方法 | |
Sá-Correia et al. | Gellan gum biosynthesis in Sphingomonas paucimobilis ATCC 31461: genes, enzymes and exopolysaccharide production engineering | |
Coplin et al. | Molecular genetics of extracellular polysaccharide biosynthesis in vascular phytopathogenic bacteria | |
EP0728841B1 (en) | DNA segments and methods for increasing polysaccharide production | |
US9938549B2 (en) | Process for producing monosaccharides | |
Nicolaus et al. | Polysaccharides from extremophilic microorganisms | |
CN1283224A (zh) | 透明质酸合酶基因及其应用 | |
US7883877B2 (en) | Compositions and methods for enhanced bacterial exopolysaccharide production | |
CN106086102A (zh) | 一种生产反式-4-羟基-l-脯氨酸的工程菌及其构建方法与应用 | |
CN101275143A (zh) | 编码透明质酸合酶的核酸及其应用方法 | |
US5985668A (en) | Sucrose metabolism mutants | |
US7285409B1 (en) | Isolated gum operon from Xyllela fastidiosa, isolated nucleic acid molecules therefrom, and uses thereof | |
JP5314955B2 (ja) | 新規微生物、イヌリナーゼ、イヌリン分解剤、イヌロオリゴ糖の製造方法及びイヌリナーゼの製造方法 | |
CN101113436B (zh) | 透明质酸合酶基因及其应用 | |
CN110438144A (zh) | 一种强化表达exoY基因提高产絮菌F2絮凝剂产量方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150617 |
|
CF01 | Termination of patent right due to non-payment of annual fee |